University of Thessaly (UTH)
Μελέτη γενετικών πολυμορφισμών μονο-νουκλεοτιδίων (SNP) που αφορούν στο μεταβολισμό της οξαλιπλατίνας σε ασθενείς με κολοορθικό καρκίνο: ανάλυση αναφορικά με την τοξικότητα και την αποτελεσματικότητα: επίδραση του μικροπεριβάλοντος στην εξέλιξη του κολοορθικού καρκίνου και άλλων νεοπλασιών του γαστρεντερικού συστήματος
Abstract
dc:descriptionGastrointestinal malignancies constitute a major cause of morbidity and mortality in the general population. Despite the initial efficacy of chemotherapeutic agents, in most cases cancer cells will develop drug resistance while patients may experience treatment side effects. In the present study we analyze the role of single nucleotide polymorphisms (SNPs) in DNA repair genes in the development of drug resistance and toxicity in colorectal cancer patients, as well as the role of the microenvironment in the resistance development of pancreatic cancer cell lines.Recent data suggest that polymorphisms in DNA repair genes may contribute to patient differences in the activity and toxicity of antineoplastic drugs, including oxaliplatin. The primary objective of this study was to evaluate the relation of ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group 1) and XD (Xeroderma pigmentosum group D protein) SNPs with tumor response and toxicity in a cohort of patients with colorectal cancer that received chemotherapy with oxaliplatin, irinotecan or 5-fluoropyrimidine base regimes. All patients supplied a peripheral blood sample from which genomic DNA was extracted from PBMCs. A polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) technique was used to determine the genotype of both XPD-751 and ERCC1-118. SNP frequency was correlated with the clinical data. In total, 243 samples patients were analyzed (111 patients received adjuvant therapy and 132 first line treatment for metastatic colorectal cancer).Both genotypes were in allelic equilibrium. There was no correlation of toxicity and survival with the polymorphisms we studied. However, KQ SNP was predictive of improved 5 year survival in patients treated with any kind of adjuvant treatment but not in those treated with oxaliplatin based treatment. This observation should be studied prospectively in a large, homogenously treated population.Caveolin-1 (Cav-1) expression has been correlated with tumor growth and chemotherapy resistance in pancreatic cancer. Furtheron, we explored the significance of Cav-1 expression in pancreatic cancer cells as compared to fibroblasts on cancer cell proliferation and chemoresistance, both in vitro and in vivo, in an immunodeficient mice model. We also aimed to evaluate the immunohistochemical expression of Cav-1 in the epithelial and stromal component of pancreatic cancer tissue specimens. Immunohistochemical staining of poorly differentiated tissue sections showed strong and weak Cav-1 expression in epithelial tumor cells and stromal fibroblasts respectively. Conversely, well differentiated areas were characterized by weak epithelial Cav-1 expression. Cav-1 down regulation in cancer cells resulted in increased proliferation in vitro, but had no impact on chemoresistance and growth gain in vivo. In contrast, reduced expression of Cav-1 in fibroblasts resulted in a growth advantage and chemoresistance of cancer cells when they were co-injected in immunodeficient mice to develop mixed fibroblast/cancer cells xenogtafts. Our results suggest that downregulation of Cav-1 in fibroblasts correlate with increased tumor proliferation rate in vivo and chemoresistance. Further studies are warranted to explore whether targeting Cav-1 in the stroma may represent a novel therapeutic approach in pancreatic cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kamposioras, Konstantinos-Vellios
- Καμποσιώρας, Κωνσταντίνος-Βέλλιος
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44634